Noul lands ₩200M grant to shift malaria test to EU's IVDR rules
What's the deal? NoulDealroom has a profile for this one. Try Dealroom →, a Korean AI-based blood and cancer diagnostics company, secured a 200,000,000 KRW (about $141,665) government grant to convert its malaria diagnostic cartridge to the European Union's IVDR regime. The funding comes from the Ministry of Health and Welfare and the Korea Health Industry Development Institute through their global regulatory response cost support program.
What's the endgame? The money covers the CE-IVDR Class C certification for Noul's miLab MAL malaria cartridge. The company will use it to build out performance data, technical documentation, and quality management systems for review by DNVDealroom has a profile for this one. Try Dealroom →, the certification body it contracted in January.
Why now? The EU switched its in vitro diagnostic rules from IVDD to the stricter IVDR, raising the bar on risk classification, testing, and clinical evidence. Class C products can no longer self-certify — they must clear review by an accredited notified body, adding cost and paperwork for manufacturers.
miLab is an on-device AI platform that automates the microscopy process from sample prep to imaging and analysis, returning results in about 15 minutes. Users swap cartridges for malaria, blood cell morphology, or cervical cytology tests; DNV is reviewing all three products, with miLab MAL first.
Why it matters: Europe now drives Noul's sales mix. Regional data for the first half of 2026 put European sales at roughly 41% of the total, up 26.2 percentage points from 14.8% in the second half of 2025.
Since miLab's model relies on repeat cartridge orders after equipment is installed, certification is the step that turns those installs into recurring revenue. Alongside the IVDR work, Noul is registering products by country, lining up distribution partners, and completing EPR registrations to meet the EU's packaging waste rules, which took general effect on August 12, 2026.
What could go wrong? The grant reduces certification costs but guarantees neither approval nor sales. Noul must pass DNV's review, manage post-market performance tracking, and adapt to country-level rules on distribution, insurance, and procurement even after securing a single CE mark.
"We secured government support at a point when our global sales structure is shifting toward the European market," said chief executive officer Lim Chan-yang (translated from Korean), adding that the company would push its CE-IVDR conversion to supply products steadily and expand in Europe.
The signal: The round is a modest one — its size sits near the 40th percentile among comparable deals — but it points to a broader reality for medtech exporters. Under IVDR, market access increasingly hinges on regulatory readiness, and public grants are becoming a tool for smaller firms to fund the compliance work that turns overseas footholds into durable revenue.
Read more: VentureSquare
Image credit: ₡ґǘșϯγ Ɗᶏ Ⱪᶅṏⱳդ
